denosumab-adet

denosumab-adet (PONLIMSI) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.

PONLIMSI is a marketed brand name for denosumab-adet. Check FDA Drugs@FDA for the current US label holder and prescribing information.

denosumab-adet has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.